| Autor: |
Toshio Katsunuma, Takao Fujisawa, Takanobu Maekawa, Kenichi Akashi, Yukihiro Ohya, Yuichi Adachi, Koji Hashimoto, Mihoko Mizuno, Takanori Imai, Mari S. Oba, Mayumi Sako, Yasuo Ohashi, Hidefumi Nakamura |
| Jazyk: |
angličtina |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Allergology International, Vol 68, Iss 3, Pp 335-341 (2019) |
| Druh dokumentu: |
article |
| ISSN: |
1323-8930 |
| DOI: |
10.1016/j.alit.2019.02.001 |
| Popis: |
Background: Although the guidelines in most countries do not recommend continuous inhalation of l-isoproterenol to treat pediatric patients with acute severe exacerbation of asthma, lower dose of l-isoproterenol has been widely used in Japan. To determine whether the efficacy of low-dose l-isoproterenol was superior to that of salbutamol, we conducted a double-blind, randomized controlled trial. Methods: Hospitalized patients aged 1–17 years were eligible if they had severe asthma exacerbation defined by the modified pulmonary index score (MPIS). Patients were randomly assigned (1:1) to receive inhalation of l-isoproterenol (10 μg/kg/h) or salbutamol (500 μg/kg/h) for 12 hours via a large-volume nebulizer with oxygen. The primary outcome was the change in MPIS from baseline to 3 hours after starting inhalation. Trial registration number UMIN000001991. Results: From December 2009 to October 2013, 83 patients (42 in the l-isoproterenol group and 41 in the salbutamol group) were enrolled into the study. Of these, one patient in the l-isoproterenol group did not receive the study drug and was excluded from the analysis. Compared with salbutamol, l-isoproterenol reduced MPIS more rapidly. Mean (SD) changes in MPIS at 3 hours were −2.9 (2.5) in the l-isoproterenol group and −0.9 (2.3) in the salbutamol group (difference −2.0, 95% confidence interval −3.1 to −0.9; P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
